The sensitivity of prostate cancer cells to manipulation of their androgen environment suggests that the testosterone flare associated with initial implementation of GnRH agonist therapy could potentially enhance the response to the subsequent reduction in testosterone levels. This evidence concerns the gene GNRH1 and prostate carcinoma.